Treats relapsing forms of multiple sclerosis (MS). ANDA 208008, held by Teva Pharms USA. Fingolimod Hydrochloride.
As of Nov 16, 2026, ANDA 208008 (Fingolimod Hydrochloride), held by Teva Pharms USA, was first approved by FDA on Jul 2, 2020, with 0 approved supplements and 0 published complete response letters.
Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fingolimod HydrochlorideEQ 0.5MG BASE · capsule;oral | Fingolimod Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters